Research progress of CD39-CD73-adenosine pathway in immune regulation of hepatocellular carcinoma
Hepatocellular carcinoma(HCC)patients accounts for 85%-90%of all primary liver cancer patients.Surgical treatment methods,represented by resection and liver transplantation,have relatively good efficacy and are currently the preferred treatment approaches for HCC,with a 5-year survival rate of 70%-80%after treatment.However,the high recurrence rate of HCC remains the greatest challenge in current liver cancer treatment.Due to the heterogeneity of HCC,the efficacy of current chemotherapy drugs and multi-kinase inhibitors is limited.It is crucial to explore new therapeutic strategies.The CD39-CD73-adenosine pathway plays a significant regulatory role in the liver microenvironment by converting pro-inflammatory extracellular adenosine triphosphate(eATP)into immunosuppressive adenosine.Targeting key molecules in this pathway for treatment has shown anti-tumor effects.Strategies of targeting the CD39-CD73-adenosine pathway and combined therapeutic strategies based on the CD39-CD73-adenosine pathway might offer more effective treatment options for HCC patients.This article reviews the biological effects and roles of the CD39-CD73-adenosine pathway in the immune regulation of HCC.
万方数据
维普
